Tag: Neuromodulation

Medical necessity “should drive all remote monitoring decisions” in SCS, expert...

The principle of medical necessity “should drive all remote monitoring decisions” relating to spinal cord stimulation (SCS) technologies, according to recommendations recently published in...

SynerFuse completes enrolment in proof-of-concept study

SynerFuse has announced that it has completed enrolment in its proof-of-concept study to evaluate the safety and tolerability of the Electric Transforaminal Lumbar Interbody...

Biotronik announces new data supporting effectiveness of RESONANCE multiphase stimulation paradigm

Biotronik Neuro has announced that results from the BENEFIT-02 trial—the “first of its kind” to clinically evaluate a multiphase stimulation paradigm—support the effectiveness of...

High-frequency spinal cord stimulation may be associated with “significant decrease” in...

High-frequency spinal cord stimulation (HF-SCS) for treating chronic refractory low back pain (CRLBP) may be associated with a significant decrease in total healthcare costs,...

Nevro announces clinical data reinforcing significant and durable benefits of 10kHz...

Nevro Corporation has announced the results from data presentations at the 25th North American Neuromodulation Society (NANS) annual meeting (13–15 January 2022; Orlando, USA) supporting...

First implant in integrated spinal fusion and DRG neuromodulation proof-of-concept study

SynerFuse has announced the first implantation in the company's proof-of-concept study, which will evaluate the safety and tolerability of simultaneously implanting spinal fusion hardware and...
spinal cord stimulation patient access

Current gaps and barriers in patient access to spinal cord stimulation

Maricela Schnur (St Luke’s Hospital, Duluth, USA) highlights a handful of socioeconomic disparities, racial differences, and psychological and psychiatric factors that currently present difficulties...
scs diabetic neuropathy

High-frequency SCS takes the stage to relieve chronic pain from diabetic...

Following the recent approval of the Senza system (Nevro) by the US Food and Drug Administration (FDA), Erika A Petersen (Little Rock, USA) discusses the...
nevro senza

Nevro announces FDA approval of high-frequency SCS therapy for painful diabetic...

Nevro has announced receipt of US Food and Drug Administration (FDA) approval for its Senza system to treat chronic pain associated with painful diabetic...

Dorsal root ganglion stimulation evokes motor responses in patients with complete...

Bilateral L4 dorsal root ganglion (DRG) stimulation has been shown to evoke strong and reproducible motor responses in the upper leg in patients with...

Mainstay Medical announces FDA approval of ReActiv8 neurostimulation system for chronic...

Mainstay Medical has announced that the US Food and Drug Administration (FDA) has approved the company’s premarket approval (PMA) application for ReActiv8, its implantable...

GTX Medical and NeuroRecovery Technologies announce merger

GTX Medical (formerly G-Therapeutics) and NeuroRecovery Technologies (NRT) have announced a merger to further the development of neuromodulation therapies to aid functional recovery of...

Immediate restoration of voluntary movement with epidural spinal cord stimulation in...

In a small cohort of patients, spinal cord stimulation has been shown to restore volitional movement in select patients with paraplegia, after intensive therapy....

CE mark approval for Stimwave’s world-first fully percutaneous spinal cord stimulator...

CE mark approval has been granted for the world’s first percutaneous injectable anchor system, SandShark. The Stimwave system is used to fixate the company’s...

Mainstay Medical ReActiv8-B clinical trial enrols first subject

The first subject has been enrolled in the ReActiv8-B Clinical Trial of the Mainstay Medical ReActiv8 device. The trial is intended to gather data...

Mainstay Medical ReActiv8-A sustains performance at one year in clinical trial

Mainstay Medical has announced the one-year results from the ReActiv8-A Clinical Trial, an international, multi-centre, prospective, single arm trial for ReActiv8 in people with...

Most patients with chronic truck or limb pain experience “substantial” pain...

Twenty-four month data from a postmarket, clinical registry have found that most patients suffering from chronic pain of the trunk and/or limbs reported “substantial”...